Sign inJoin waitlistJoin the waitlist

Roland Walter

Professor, Translational Science and Therapeutics Division, Fred Hutch · University of Washington School of Medicine

Credentials: · · · · · ·

History

University of Washington School of Medicine
Present
University of Washington School of Medicine
Present
University of Washington School of Medicine
Present

University of Washington-Seattle Campus
1999–2000
University Hospital
1996–1999
Epidemiology, Clinical Research, University of Washington
UNIV ZURICH, MED FAK, ZURICH, SWITZERLAND
1992–1996

Research

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Review · Blood · 2018 · 856 citations
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
Blood · 2021 · 650 citations
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Journal of Clinical Oncology · 2019 · 557 citations

EE
Elihu Estey
89 papers
Frederick Appelbaum
63 papers
Anna Halpern
46 papers · 3 as a fellow
PH
Paul Hendrie
40 papers
Pamela Becker
38 papers
Mary-Elizabeth Percival
34 papers
Brenda Sandmaier
32 papers
Brent Wood
31 papers
SB
Sarah Buckley
27 papers · 20 as a resident
Bart Scott
21 papers
Harry Erba
20 papers
JP
John Pagel
20 papers

Grants

Optimizing CD45-Targeted Astatine-211-Radioimmunotherapy for Malignant and Non-Malignant Blood Disorders
National Cancer Institute · R01
Contact PI · $716.3K · Fred Hutchinson Cancer Center
2026–2031
Base-Edited Hematopoietic Stem and Progenitor Cells To Enable Safe Use Of Highly Potent CD33-Targeted Radioimmunotherapy
National Cancer Institute · R01
Contact PI · $3.5M · Fred Hutchinson Cancer Center
2022–2027
Preventing Relapse After Non-Myeloablative Stem Cell Transplantation: The Final Challenge
National Cancer Institute · P01
PI · $2.1M · Fred Hutchinson Cancer Center
1999–2027
Novel Approaches to CD33-Directed Radioimmunotherapy
National Cancer Institute · R37
Contact PI · $4.4M · Fred Hutchinson Cancer Center
2019–2026

Clinical trials

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients
Principal investigator · Completed · Phase 2
Fred Hutchinson Cancer Center
2020–2026
Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm
Principal investigator · Completed · Phase 1, Phase 2
Fred Hutchinson Cancer Center
2018–2021
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS
Principal investigator · Completed · Phase 1, Phase 2
Fred Hutchinson Cancer Center
2016–2018
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Principal investigator · Completed · Phase 1, Phase 2
Fred Hutchinson Cancer Center
2014–2018